Statin Addition to Chemotherapy for Advanced Pancreatic Cancer

Korábbi kezelés

• Patients who have previously taken lipid-lowering drugs (such as statins, fibrates, ezetimibe, or PCSK9 inhibitors).

Más betegség

• Patients with poor condition can not tolerate chemotherapy.
• Impaired organ functions: heart failure (New York Heart Association III- IV), coronary heart disease, myocardial infarction within 6 months, severe cardiac arrhythmia and respiratory failure.
• Patients diagnosed with other cancer within 5 years.

Egyéb

• Patients who are taking warfarin, verapamil, clopidogrel, digoxin, amiodarone, etc.
• Patients who are pregnant or breastfeeding.
• Patients enrolled in other clinical trials or incompliant of regular follow up.
• Patients who did not provide an informed consent.

• Age≥18 years old and ≤80 years old.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
• Histologically or cytologically confirmed local advanced/metastatic pancreas adenocarcinoma.
• Imaging studies confirmed the diagnosis of locally advanced or metastatic pancreatic cancer patients.
• The patients were in the plateau stage after chemotherapy, as indicated by the CA19-9 values (with CA19-9 negative patients referenced against CEA or CA-125) fluctuating by less than 20% over an interval of more than 3 weeks.
• Life expectancy of greater than 90 days, as judged by the investigator.
• Routine blood test: absolute neutrophil count>1500/mm3, platelet>100000/ mm3.
• Normal liver function: serum total bilirubin≤2.0mg/dl, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 times of the upper limit of normal value.
• Normal kidney function: serum creatinine<1.5 times of the upper limit of normal value or creatinine clearance rate>45ml/min.
• No severe comorbidities.